SECURON IV

Active substance: VERAPAMIL HYDROCHLORIDE

View full screen / Print PDF » Download PDF ⇩

Transcript
which spread over your teeth, or (in males)
if your breasts swell. These effects are very
rare and resolve on stopping treatment.

Patient Information Leaflet

What Securon IV looks like:
The product is available in 2 ml ampoules,
each containing 5 
mg of verapamil
hydrochloride.

If you experience any other unusual
symptoms after you have received
Securon IV, tell your doctor, nurse or
pharmacist.

Securon® IV 2.5 mg/ml
aqueous solution for
intravenous injection

Marketing Authorisation and Manufacturer’s
Details
Marketing Authorisation Holder:
Abbott Laboratories Ltd., Abbott House,
Vanwall Business Park, Vanwall Road,
Maidenhead, Berkshire, SL6 4XE,
United Kingdom.
Manufacturer:
FAMAR HEALTH CARE SERVICES MADRID S.A.U.
Avda. de Leganés, 62 28923 Alcorcón-Madrid,
Spain.

Reporting of side effects
Also you can help to make sure that
medicines remain as safe as possible by
reporting any unwanted side effects via the
internet at www.mhra.gov.uk/yellowcard.
Alternatively you can call Freephone 0808
100 3352 (available from 10 a.m. to 2 p.m.
Mondays to Fridays) or fill in a paper form
available from your local pharmacy.

Securon IV belongs to a group of medicines
called calcium channel blockers; its active
ingredient is verapamil hydrochloride. Securon
IV is used to treat abnormal heart rhythms
such as an irregular or rapid heart rate.

Verapamil Hydrochloride BP

2. hat should you know before receiving
W
Securon IV?
IMPORTANT INFORMATION

If
 the answer to any of the following
questions is ‘YES’ please tell your doctor or
pharmacist BEFORE receiving Securon IV:

Read all of this leaflet carefully before
you receive Securon IV
•  eep this leaflet as you may need to
K
read it again
•  his leaflet provides a summary of
T
the information currently available on
Securon IV
•  or further information or advice ask
F
your doctor or ward pharmacist
•  ell your doctor if you experience any
T
side effects

This leaflet was last revised in April 2013.

5. How should Securon IV be stored?
Do not store above 30°C and protect from
light. The doctor or nurse will check that
the expiry date on the label has not passed
before you are given the injection. It should
NOT be used after the expiry date printed
on the label.

Leaflet contents:
1. What is Securon IV and what is it used for?
2.
What should you know before receiving
Securon IV?
3. How will you receive Securon IV?
4. Possible side effects
5. How should Securon IV be stored?
6. Further information about Securon IV

6. Further Information
What Securon IV contains:
Each ampoule of injection solution contains
2.5 
mg per ml verapamil hydrochloride
ph Eur in water for injections and sodium
chloride, with hydrochloric acid as pH
adjuster.

1. What is Securon IV and what is it used
for?

4

1

• Are you are sensitive (allergic) to the active
ingredient verapamil hydrochloride or any
of the other ingredients in the medicine?
(See section 6)
• Are you pregnant, planning to become
pregnant or breast-feeding?
• Do you have kidney problems?
• Do you have very low blood pressure?
• Do you have an abnormally slow, fast or
irregular heartbeat?
• Do you have or have you ever suffered
from heart problems such as heart failure,
or the heart condition called WolffParkinson-White syndrome?
• Are you currently receiving intravenous
beta-blockers, e.g. atenolol, propranolol?
• Do you have a condition where the
nerve to muscle transmission is affected
e.g. myasthenia gravis, Lambert-Eaton
syndrome, advanced Duchenne muscular
dystrophy?

--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

rhythms), total AV block with total AV
dissociation, escape rhythm, asystole,
bradycardia up to high degree AV block
and sinus arrest, hyperglycaemia, stupor
and metabolic acidosis. Fatalities have
occurred as a result of overdose.
Treatment of overdosage depends on
the type and severity of symptoms. The
specific antidote is calcium, e.g. 10-20
ml of 10% calcium gluconate solution
i.v. (2.25-4.5 mmol) if necessary by
repeated injection or continuous infusion
(e.g. 5 mmol/hour). The usual emergency
measures for acute cardiovascular
collapse should be applied and
followed by intensive care. Verapamil
hydrochloride cannot be removed by
haemodialysis. Similarly, in the case
of second or third degree AV block,
atropine, orciprenaline, isoprenaline
and if required, pacemaker therapy
should be considered. If there are signs
of myocardial insufficiency, dopamine,
dobutamine, cardiac glycosides or
calcium gluconate (10-20 ml of a 10%
solution) can be administered.
In the case of hypotension, after
appropriately positioning the patient,
dopamine, dobutamine or noradrenaline
may be given.

Securon® IV 2.5 mg/ml
aqueous solution for
intravenous injection

Administrative Data
7. Marketing Authorisation Holder
Abbott Laboratories Ltd.,
Abbott House, Vanwall Business Park,
Vanwall Road, Maidenhead, Berkshire,
SL6 4XE, United Kingdom.
Date of preparation: April 2013

Verapamil Hydrochloride BP
1. Trade Name of the Medicinal Product
Securon IV
2. Qualitative and Quantitative Composition
Verapamil Hydrochloride BP 2.5 mg/ml
3. Pharmaceutical Form
Aqueous solution for intravenous
injection.
4. Clinical Particulars
4.1. Therapeutic Indications
Securon IV is indicated for the treatment of
paroxysmal supraventricular tachycardia
and the reduction of ventricular rate in
atrial flutter/fibrillation.
4.2. Posology and Method of Administration
For slow intravenous injection.
Adults: 5-10 mg by slow intravenous
injection over a period of 2 minutes.
The patient should be observed
continuously, preferably under ECG and
blood pressure control. If necessary, e.g.
in paroxysmal tachycardia, a further 5
mg may be given after 5 to 10 minutes.
Children: Securon IV must always be
administered under ECG monitoring in
young patients.
0-1 year: 0.1-0.2 mg/kg bodyweight
(usual single dose range: 0.75-2 mg).
1-15 years: 0.1-0.3 mg/kg bodyweight
(usual single dose range: 2-5 mg).
The dose may be repeated after 30
minutes if necessary. Many cases are
controlled by doses at the lower end
of the range. The injection should be
stopped at the onset of the desired
effect.
Elderly: The dosage should be
administered over 3 minutes to minimise
the risk of adverse effects.
Dosage in impaired liver and renal
function: Significant hepatic and renal
impairment should not increase the
effects of a single intravenous dose but
may prolong its duration of action.
For use with beta-blocker therapy,
see ‘Contra-indications’ and ‘Special
Warnings and Precautions for Use’.
4.3. Contra-indications
Hypersensitivity to the active substances
or excipients.
Cardiogenic shock; acute myocardial
infarction complicated by bradycardia,
marked hypotension or left ventricular
failure; second or third degree AV block
(except in patients with a functioning
artificial ventricular pacemaker); sinoatrial block; sick sinus syndrome (except
in patients with a functioning artificial
ventricular pacemaker); uncompensated
heart failure; bradycardia of less than
50 beats/minute; hypotension of less

5. Pharmacological Properties
5.1. Pharmacodynamic Properties
Verapamil is a calcium antagonist
which blocks the inward movement of
calcium ions in cardiac muscle cells,
in smooth muscle cells of the coronary
and systemic arteries and in cells of
the intracardiac conduction system.
Because of its effect on the movement
of calcium in the intracardiac conduction
system, verapamil reduces automaticity,
decreases conduction velocity and
increases the refractory period.
5.2. Pharmacokinetic Properties
Following intravenous infusion in man,
verapamil is eliminated bi-exponentially
with a rapid distribution phase (half-life
about 4 minutes) and a slower terminal
elimination phase (half-life 2-5 hours).
Plasma protein binding of verapamil is
more than 90%. Renal insufficiency does
not affect the kinetics of verapamil. In
patients with liver cirrhosis, elimination
half life is prolonged.
5.3. Preclinical Safety Data
Not applicable.
6. Pharmaceutical Particulars
6.1. List of Excipients
Water for injections, sodium chloride
(8.5 mg/ml), hydrochloric acid 10% as
pH adjuster.
6.2. Incompatibilities
Securon IV is incompatible with alkaline
solutions.
6.3. Shelf Life
36 months.
6.4. Special Precautions for Storage
Do not store above 30°C. Protect from
light.
4

1
11503653-00

11503653-00_d5

than 90 mmHg systolic; simultaneous
administration of intravenous betablockers.
Patients with atrial flutter/fibrillation in the
presence of an accessory pathway (e.g.
WPW syndrome) may develop increased
conduction across the anomalous
pathway and ventricular tachycardia may
be precipitated.
4.4.  pecial Warnings and Precautions for
S
Use
Verapamil
may
affect
impulse
conduction. For this reason, Securon IV
should be used with caution in patients
with bradycardia or first degree AV block.
Verapamil may affect left ventricular
contractility; this effect is small and
normally not important but cardiac failure
may be precipitated or aggravated. In
patients with poor ventricular function,
therefore, Securon IV should only be
given after cardiac failure has been
controlled with appropriate therapy, e.g.
digitalis.
Although
the
pharmacokinetics
of verapamil in patients with renal
impairment are not affected, caution
should be exercised and careful patient
monitoring is recommended. Verapamil
is not removed during dialysis.
Caution should be exercised in treatment
with HMG CoA reductase inhibitors (e.g.,
simvastatin, atorvastatin or lovastatin)
for patients taking verapamil. These
patients should be started at the lowest
possible dose of verapamil and titrated
upwards. If verapamil treatment is to
be added to patients already taking
an HMG CoA reductase inhibitor (e.g.,
simvastatin, atorvastatin or lovastatin),
refer to advice in the respective statin
product information.
Use with caution in the presence of
diseases in which neuromuscular
transmission is affected (myasthenia
gravis,
Lambert-Eaton
syndrome,
advanced
Duchenne
muscular
dystrophy)
4.5. 
Interactions with other medicinal
products and other forms of
Interaction
In rare instances, including when patients
with severe cardiomyopathy, congestive
heart failure or recent myocardial infarction
were given intravenous beta-adrenergic
blocking
agents
or
disopyramide
concomitantly with intravenous verapamil
hydrochloride, serious adverse effects
have occurred. Concomitant use of
verapamil hydrochloride with agents that
decrease adrenergic function may result
in an exaggerated hypotensive response.
In vitro metabolic studies indicate
that
verapamil
hydrochloride
is
metabolized by cytochrome P450
CYP3A4, CYP1A2, CYP2C8, CYP2C9
and CYP2C18. Verapamil has been
shown to be an inhibitor of CYP3A4
enzymes and P-glycoprotein (P-gp).
Clinically significant interactions have
been reported with inhibitors of CYP3A4

FOR THE INFORMATION
OF THE MEDICAL PROFESSION

6.5. Nature and Contents of Container
2 ml glass ampoule (hydrolytic type 1)
containing 5 mg verapamil.
Pack size: 5 x 2 ml ampoules.
6.6. Instruction for Use/Handling
None.

11503653-00

FRONT

Other important information
Do NOT drink grapefruit juice whilst taking
Securon IV as it can effect the absorption
of this medicine. This does not occur with
other fruit juices such as orange, apple or
tomato juice.

• Aspirin, a non-steroidal anti-inflammatory
painkiller (NSAID) used to relieve pain and
reduce fever
• Almotriptan, used to treat migraine
• Midazolam, used as a sedative or
anaesthetic
• Theophylline, used to treat asthma
• Cimetidine, used to treat indigestion or
stomach ulcers
• Rifampicin, used to treat tuberculosis and
other types of infection
• Carbamazepine,
phenytoin
or
phenobarbital (phenobarbitone). These
medicines are used as anti-convulsants
• Ritonavir, used to treat HIV
• Erythromycin,
clarithromycin
and
telithromycin, used to treat types of infection
• Colchicines or sulfinpyrazone, used to
treat gout

Your doctor will monitor you closely if:
• You have any other heart problems in
addition to the one you are being treated for
• You need any other medication to treat
your abnormal heart rhythm
• You need to be given an anaesthetic
You MUST tell your doctor if you are
taking any medicines with or without a
prescription or have recently taken any
of the following medicines:
• Beta-blockers used to treat high blood
pressure and heart conditions (these
include
atenolol,
propranolol
and
metoprolol)
• Alpha blockers used to treat high blood
pressure and heart conditions (these
include prazosin and terazosin)
• Medicines know as ‘statins’ such as
atorvastatin, lovastatin, simvastatin used
to lower cholesterol levels
• Any other medicine for high blood
pressure or an abnormal heart beat
(arrhythmia) such as quinidine, flecainide,
disopyramide, digoxin and digitoxin
• Medicines used to treat depression
(including the herbal product St John’s
Wort), anxiety or psychosis. These may
include imipramine, buspirone and lithium
• Medicines known as immunosuppressants
such as ciclosporin, sirolimus, everolimus
and tacrolimus. These are used to prevent
organ transplant rejection
• Glibenclamide, used to treat certain types
of diabetes

4. Possible side effects
As with all medicines, Securon IV can cause
side effects. Securon IV affects the rhythm
of the heart, but may also slow down the
heart rate and cause a drop in blood
pressure in some patients.
The medical team will therefore monitor you
closely during your treatment.

3. How will you receive Securon IV?

If you experience any of the following rare
side effects tell your doctor IMMEDIATELY:
• Changes in heart rhythm, chest pains for
the first time or chest pains becoming
frequent
• Swollen ankles
• Unexpected wheezing, difficulty breathing,
swelling of the mouth, lips or tongue,
itching or a severe skin rash
• Yellowing of the skin or eyes, a fever or
tenderness around the middle. These are
signs that your liver may not be functioning
as well as usual

Securon IV is given to you by injection into a
vein (Intravenously). This will be carried out
by a doctor.
The dose will vary according to your condition
this will be decided by the doctor. The
medical team in the hospital may monitor
your blood pressure and ECG (The electrical
activity of the heart) throughout your
treatment. The usual doses are as follows

Driving and using machinery

Adults:
5-10 mg by slow intravenous injection over
a period of 2 minutes.
In elderly patients, the injection may be
given at a slower rate.
If necessary, an extra 5 mg may be injected
after 5 to 10 minutes.
Children:
0-1 Year: 0.1 to 0.2 mg per kg bodyweight
1-15 years: 0.1 to 0.3 mg per kg bodyweight
The injection may be repeated after 30
minutes, if necessary.

Verapamil may affect your ability
to drive or operate machinery,
you MUST check with your doctor
before you do so.
This is particularly important if you
have had prolonged intravenous
therapy or if you have switched to
oral (tablet) treatment.
Pregnancy and breast feeding
Please discuss with your doctor if you are
pregnant, planning to become pregnant or
are breast feeding.
2

Other side effects with verapamil include
flushing of the face or neck, sweating,
headaches, tiredness, seizures, dizziness,
vertigo, nervousness, movement disorders,
abnormal discomfort, nausea, abdominal
pain or vomiting.
Other side effects may sometimes occur
with long-term verapamil treatment. Tell
your doctor if you develop swollen gums
3

--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

causing elevation of plasma levels of
verapamil hydrochloride while inducers
of CYP3A4 have caused a lowering of
plasma levels of verapamil hydrochloride,
therefore, patients should be monitored
for drug interactions.
The following are potential drug
interactions associated with verapamil:
Acetylsalicylic acid
Concomitant use of verapamil with
aspirin may increase the risk of bleeding.
Alpha blockers
Verapamil may increase the plasma
concentrations of prazosin and terazosin
which may have an additive hypotensive
effect.
Antiarrhythmics
Verapamil may slightly decrease the
plasma clearance of flecainide whereas
flecainide has no effect on the verapamil
plasma clearance.
Verapamil may increase the plasma
concentrations of quinidine.
The combination of verapamil and
antiarrhythmic agents may lead to
additive cardiovascular effects (e.g.
AV block, bradycardia, hypotension,
heart failure). Care must be exercised
if Securon IV is combined with antiarrhythmic agents by any route.
Anticonvulsants
Verapamil may increase the plasma
concentrations
of
carbamazepine.
This may produce side effects such as
diplopia, headache, ataxia or dizziness.
Verapamil may also increase the plasma
concentrations of phenytoin.
Antidepressants
Verapamil may increase the plasma
concentrations of imipramine.
Antidiabetics
Verapamil may increase the plasma
concentrations
of
glibenclamide
(glyburide).
Anti-infectives
Rifampicin may reduce the plasma
concentrations of verapamil which
may produce a reduced blood
pressure lowering effect. Erythromycin,
clarithromycin and telithromycin may
increase the plasma concentrations of
verapamil.
Antineoplastics
There is no significant difference between
the pharmacokinetic parameters of
doxorubicin with intravenous verapamil
administration.
Barbiturates
Phenobarbital may reduce the plasma
concentrations of verapamil.
Benzodiazepines and other anxiolytics
Verapamil may increase the plasma
concentrations of buspirone and
midazolam.
Beta blockers
Verapamil may increase the plasma
concentrations of metoprolol and
propranolol which may lead to additive
cardiovascular effects (e.g. AV block,
bradycardia, hypotension, heart failure).

11503653-00_d5

2

Fluvastatin, pravastatin and rosuvastatin
are not metabolized by CYP3A4 and are
less likely to interact with verapamil.
Lithium
Serum levels of lithium may be reduced.
However there may be increased
sensitivity to lithium causing enhanced
neurotoxicity.
Neuromuscular
blocking
agents
employed in anaesthesia
The effects may be potentiated.
Protein-bound drugs
As verapamil hydrochloride is highly
bound to plasma proteins, it should be
administered with caution to patients
receiving other highly protein-bound
drugs.
Serotonin receptor agonists
Verapamil may increase the plasma
concentrations of almotriptan.
Theophylline
Verapamil may increase the plasma
concentrations of theophylline.
Uricosurics
Sulfinpyrazone may reduce the plasma
concentrations of verapamil which may
produce a reduced blood pressure
lowering effect.
Other
St. John’s Wort may reduce the plasma
concentrations of verapamil, whereas
grapefruit juice may increase the plasma
concentrations of verapamil.
4.6. Pregnancy and Lactation
Although animal studies have not shown
any teratogenic effects, verapamil should
not be given during the first trimester
of pregnancy unless, in the clinician‘s
judgement, it is essential for the welfare
of the patient. Verapamil crosses the
placental barrier and can be detected
in umbilical vein blood at delivery. Also,
verapamil is excreted in human breast
milk.
Limited
human
data
from
oral
administration has shown that the
infant relative dose of verapamil is low
(0.1-1% of the mother’s oral dose) and
that verapamil use may be compatible
with breastfeeding. However, there are
currently no reports of verapamil injection
or infusion use during breastfeeding.
Due to the potential for serious adverse
reactions in nursing infants, verapamil
should only be used during lactation if it
is essential for the welfare of the mother.
4.7. Effects on Ability to Drive and Use
Machines
None stated.
4.8. Undesirable Effects
Adverse events observed in clinical
trials are depicted in the following
table. Within each system organ class,
the adverse drug reactions are ranked
under headings of frequency, using the
following convention: common (>1/100,
<1/10), uncommon (>1/1,000, <1/100),
rare (>1/10,000, <1/1,000), very rare
(<1/10,000), including isolated reports.

Securon IV should not be given in
combination with intravenous betablocker therapy and care must be
exercised if Securon IV is combined with
oral beta-blocker therapy.
Cardiac glycosides
Verapamil may increase the plasma
concentrations of digitoxin and digoxin.
Verapamil has been shown to increase
the serum concentration of digoxin and
caution should be exercised with regard
to digitalis toxicity. The digitalis level
should be determined and the glycoside
dose reduced, if required.
Colchicine
Colchicine is a substrate for both CYP3A
and the efflux transporter, P-glycoprotein
(P-gp). Verapamil is known to inhibit
CYP3A and P-gp. When verapamil and
colchicine are administered together,
inhibition of P-gp and/or CYP3A by
verapamil may lead to increased
exposure to colchicine. Combined use is
not recommended.
H2 Receptor antagonists
Cimetidine may increase the plasma
concentrations of verapamil following
intravenous verapamil administration.
HIV antiviral agents
Due to the metabolic inhibitory potential
of some of the HIV antiviral agents, such
as ritonavir, plasma concentrations of
verapamil may increase. Caution should
be used or dose of verapamil may be
decreased.
Immunosuppressants
Verapamil may increase the plasma
concentrations
of
ciclosporin,
everolimus, sirolimus and tacrolimus.
Inhaled anaesthetics
When used concomitantly, inhalation
anaesthetics and calcium antagonists,
such as verapamil hydrochloride, should
each be titrated carefully to avoid
additive cardiovascular effects (e.g. AV
block, bradycardia, hypotension, heart
failure).
Lipid lowering agents
Verapamil may increase the plasma
concentrations atorvastatin lovastatin
and simvastatin.
Treatment with HMG CoA reductase
inhibitors (e.g., simvastatin atorvastatin
or lovastatin) in a patient taking verapamil
should be started at the lowest possible
dose and titrated upwards. If verapamil
treatment is to be added to patients
already taking an HMG CoA reductase
inhibitor (e.g., simvastatin, atorvastatin
or lovastatin), consider a reduction in the
statin dose and retitrate against serum
cholesterol concentrations.
Atorvastatin has been shown to increase
verapamil levels. Although there is
no direct in vivo clinical evidence,
there is strong potential for verapamil
to significantly affect atorvastatin
pharmacokinetics in a similar manner to
simvastatin or lovastatin. Consider using
caution when atorvastatin and verapamil
are concomitantly administered.

System Organ
Class
Nervous system
disorders
Cardiac disorders/
vascular disorders

Gastrointestinal
disorders

BACK

common

- dizziness
- headache

common

- bradycardia
- hypotension
uncommon - tachycardia
uncommon - nausea
- abdominal pain

Cases of seizures during verapamil
hydrochloride injection have been
reported.
In rare cases of hypersensitivity,
bronchospasm accompanied by pruritis
and urticaria has been reported.
Other Reactions from Postmarketing
Surveillance or Phase IV Clinical Trials
Other adverse events reported with
verapamil are listed below by system
organ class:
Psychiatric disorders: on rare occasions,
nervousness has been reported.
Nervous system disorders: somnolence
and extrapyramidal syndrome.
Ear and labyrinth disorders: vertigo.
Cardiac disorders/vascular disorders:
decreased myocardial contractility has
been reported. On rare occasions, 2nd
and 3rd block may occur and in extreme
cases, this may lead to asystole. The
asystole is usually of short duration and
cardiac action returns spontaneously
after a few seconds, usually in the
form of sinus rhythm. If necessary,
the procedures for the treatment of
overdosage should be followed as
described below. On rare occasions,
flushing has been reported.
Gastrointestinal
disorders:
gingival
hyperplasia may occur very rarely when
the drug is administered over prolonged
periods, and is fully reversible when the
drug is discontinued. On rare occasions,
vomiting has also been reported.
Skin and subcutaneous tissue disorders:
Steven-Johnson syndrome, erythema
and hyperhidrosis.
Reproductive
system
and
breast
disorders: On very rare occasions,
gynaecomastia has been observed in
elderly male patients under long-term
verapamil treatment; this was fully
reversible in all cases when the drug was
discontinued.
Investigations: A reversible impairment
of liver function characterized by an
increase of transaminase and/or alkaline
phosphatase may occur on very rare
occasions during verapamil treatment
and is most probably a hypersensitivity
reaction.
4.9. Overdose
The
symptoms
of
overdosage
include hypotension, shock, loss of
consciousness, first and second degree
AV block (frequently as Wenckebach’s
phenomenon with or without escape
3

11503653-00

Frequency Undesirable
Effects

11503653-00

Use by:

11503652-00_d4

5 x 2 ml Ampoules
Aqueous solution for slow intravenous injection.
Batch:

2.5 mg/ml
Verapamil Hydrochloride BP

Securon® IV
M075

11503652-00

Aqueous solution for slow intravenous injection.
5 x 2 ml Ampoules

2.5 mg/ml
Verapamil Hydrochloride BP

Securon® IV

Aqueous solution for slow intravenous injection.
5 x 2 ml Ampoules

2.5 mg/ml

Verapamil Hydrochloride BP

Securon® IV

MA Holder:
Abbott Laboratories Ltd.
Abbott House, Vanwall Business Park,
Vanwall Road, Maidenhead, Berkshire,
SL6 4XE, United Kingdom
PL 00037/0367

POM

Each ampoule contains verapamil hydrochloride BP 2.5 mg/ml in water for injections and
sodium chloride, with hydrochloric acid as pH adjuster.
Please read the enclosed information leaflet.
A leaflet for the patient is also included.
Do not store above 30°C. Protect from light.
Keep all medicines out of the reach and sight of children.

11503651-00

M075

Securon® IV

Verapamil Hydrochloride BP

2.5 mg/ml

11503651-00_d4

Use by:

Batch:

2 ml
For slow intravenous injection.
Abbott Laboratories Ltd.
PL 00037/0367

Expand view ⇕

Source: Medicines and Healthcare Products Regulatory Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide
(web4)